Breaking News Instant updates and real-time market news.

FOE

Ferro

$12.58

0.07 (0.56%)

, APYX

Apyx Medical

$7.22

0.24 (3.44%)

18:59
11/11/19
11/11
18:59
11/11/19
18:59

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Ferro (FOE) up 16.7%... Apyx Medical (APYX) up 13.3%... Kemet Corp (KEM) up 12.9%... ICU Medical (ICUI) up 11.0%... Lonestar Resources (LONE) up 10.8%... Grocery Outlet (GO) up 7.7%... Cumulus Media (CMLS) up 6.6%... Fibrogen (FGEN) up 2.3%... DXC Technology (DXC) up 1.1%. ALSO HIGHER: Craft Brew (BREW) up 121.6% after Anheiser Busch agreed to buy remaining stake at $16.50 per share... Live Nation (LYV) up 1.1% after being upgraded to Outperform at Evercore. DOWN AFTER EARNINGS: Fluent (FLNT) down 19.7%... Asure Software (ASUR) down 15.1%... UGI Corp (UGI) down 7.0%... Hudbay Minerals (HBM) down 5.7%... Farmland Partners (FPI) down 2.0%. ALSO LOWER: Reata Pharma (RETA) down 5.9% after phase 3 results in study of bardoxolone methyl... J2 Global (JCOM) down 3.1% after convertible denb offering... PG&E (PCG) down 1.6% after reports company offered $13.5% compensation to fire victims. Movers as of 18:45ET.

FOE

Ferro

$12.58

0.07 (0.56%)

APYX

Apyx Medical

$7.22

0.24 (3.44%)

KEM

Kemet

$23.03

-0.51 (-2.17%)

ICUI

ICU Medical

$168.41

1.43 (0.86%)

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

GO

Grocery Outlet

$31.09

-0.06 (-0.19%)

CMLS

Cumulus Media

$13.59

0.07 (0.52%)

FGEN

FibroGen

$35.37

-6.24 (-15.00%)

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

BREW

Craft Brew

$7.33

0.06 (0.83%)

LYV

Live Nation

$64.47

1.31 (2.07%)

FLNT

Fluent

$2.54

0.11 (4.53%)

ASUR

Asure Software

$9.20

0.01 (0.11%)

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

HBM

Hudbay Minerals

$3.66

-0.09 (-2.40%)

FPI

Farmland Partners

$6.66

-0.125 (-1.84%)

RETA

Reata Pharmaceuticals

$213.52

1.48 (0.70%)

JCOM

j2 Global

$100.62

0.23 (0.23%)

PCG

PG&E

$6.24

-0.23 (-3.55%)

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

  • 09

    Dec

  • 07

    Jan

FOE Ferro
$12.58

0.07 (0.56%)

10/15/19
WELS
10/15/19
INITIATION
Target $12
WELS
Market Perform
Ferro initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Michael Sison initiated coverage of Ferro with a Market Perform rating and $12 price target.
10/15/19
WELS
10/15/19
INITIATION
Target $12
WELS
Market Perform
Ferro initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Michael Sison initiated coverage of Ferro with a Market Perform rating and $12 price target. The analyst said the company's near-term earnings outlook is "challenging" and estimated its 2020 recovery would be driven by cost savings, with "little help from volumes growth." Sison does not see a good catalyst for the company, which he noted has high exposure to Europe, China, the automotive and tile markets.
08/01/19
BUCK
08/01/19
DOWNGRADE
Target $16
BUCK
Neutral
Ferro downgraded to Neutral on auto, EU construction headwinds at Buckingham
As previously reported, Buckingham analyst Dmitry Silversteyn downgraded Ferro to Neutral from Buy as he sees declines in European construction demand and global auto builds weighing on results well into 2020. He expects destocking and low demand remaining in FY19 and sees no improvement in customer order patterns until the macro environment improves, said Silversteyn, who cut his price target on Ferro shares to $16 from $21.
08/08/19
BMOC
08/08/19
NO CHANGE
Target $15
BMOC
Market Perform
Ferro price target lowered to $15 from $20 at BMO Capital
BMO Capital analyst John McNulty lowered his price target on Ferro to $15 and kept his Market Perform rating after its below-consensus Q2 revenue reported last week. The analyst notes that the company's earnings visibility remains difficult as distributors take a shorter term approach in light of the continued macro uncertainty and reduced consumer spending, with slowing economy in Europe and destocking in the auto and construction end-markets.
APYX Apyx Medical
$7.22

0.24 (3.44%)

05/08/19
PIPR
05/08/19
NO CHANGE
Target $7
PIPR
Overweight
Apyx Medical price target lowered to $7 from $10 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien lowered his price target on Apyx Medical to $7 after its Q1 results, adjusting his model after the company indicated that its pursuit of a dermal resurfacing indication with the FDA would be outside of the 2019 timeline. The analyst keeps his Overweight rating however and expects Apyx Medical's growth to remain healthy thanks to its "international expansion and core utilization in the US."
04/02/19
PIPR
04/02/19
NO CHANGE
Target $10
PIPR
Overweight
Piper continues to believe Apyx Medical will receive 510k clearance
Apyx Medical's decision to withdraw its 510k submission for dermal resurfacing following FDA pushback on various aspects of their study removes a source of upside and will "no doubt give legs to some of the theories floated in the short report," Piper Jaffray analyst Matt O'Brien tells investors in a research note. However, the analyst continues to believe that once Apyx "irons out" some of its clinical hurdles, the company will receive this clearance. Additionally, O'Brien feels that the product's use off-label for these procedures is likely reflective of J-Plasma's "unique utility in these situations," which allows him to remain constructive on the stock. He reiterates an Overweight rating on Apyx Medical with a $10 price target.
04/02/19
JMPS
04/02/19
NO CHANGE
Target $8
JMPS
Outperform
Apyx Medical price target lowered to $8 from $12 at JMP Securities
JMP Securities analyst David Turkaly lowered his price target on Apyx Medical shares to $8 from $12 after the company said it will voluntarily withdraw its 510(k) application for the use of its Renuvion product in dermal resurfacing procedures. Despite his belief that negative investor sentiment could be priced into the stock in the near-term, Turkaly said Apyx is still a significant grower and he still expects over 50% revenue growth in both 2019 and 2020, leading him to keep an Outperform rating on the shares.
03/14/19
PIPR
03/14/19
NO CHANGE
Target $10
PIPR
Overweight
Apyx Medical posted another solid quarter, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says Apyx Medical posted another solid quarter in-line with its preannouncement, highlighted by "strong advanced energy growth off a tough comp." While the company's expense guidance may make the earnings outlook a little less favorable in the near-term, given the light penetration into this $1.5B market and the potential for several international expansions in 2019, its growth "should remain healthy for many years," O'Brien tells investors in a research note. He encourages risk tolerant investors to own the name and reiterates an Overweight rating on Apyx Medical with a $10 price target.
KEM Kemet
$23.03

-0.51 (-2.17%)

09/13/19
09/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Kemet (KEM) upgraded to Buy from Hold at Stifel with analyst Matthew Sheerin stating that while the company is facing headwinds similar to competitors amid weakening demand and an inventory correction, its fundamentals have held up significantly better than comps due primarily to its product portfolio. 2. Advance Auto Parts (AAP) upgraded to Buy from Neutral at Citi with analyst Gregory Badishkanian saying same-store sales momentum, assortment optimization and omni-channel initiatives should drive sales growth. 3. M.D.C. Holdings (MDC) upgraded to Strong Buy from Outperform at Raymond James with analyst Buck Horne noting the company's released preliminary Q3 net order activity through July and August is tracking "dramatically ahead" of his prior expectations. 4. Etsy (ETSY) upgraded to Outperform from Neutral at Wedbush with analyst Ygal Arounian telling investors he now sees a critical mass of new initiatives, highlighted by Etsy Ads and free shipping, that can drive stronger GMS growth and margin expansion over time. 5. Acadia (ACAD) upgraded to Outperform from Market Perform at SVB Leerink with analyst Marc Goodman citing the recently announced results from the Phase 3 HARMONY study in Dementia Related Psychosis. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/19
STFL
07/11/19
NO CHANGE
Target $15
STFL
Hold
Vishay price target lowered to $15 after pre-announcement at Stifel
After Vishay (VSH) pre-announced June quarter sales and gross margins that came below its previous guidance, citing weaker demand, primarily from distribution, Stifel analyst Matthew Sheerin said he thinks the news "should come as no surprise to investors" considering the recent negative tone from several component suppliers and distributors. However, the magnitude of Vishay's miss reflects a deeper correction and increased pricing pressure, said Sheerin, who thinks the correction could last well into the first half 2020. Given the warning, he lowered his estimates and cut his price target on Vishay shares to $15 from $18 and keeps a Hold rating on the stock. Sheerin added that he sees risks to estimates for a number of component suppliers, particularly those with high exposure to distribution, such as AVX (AVX), Kemet (KEM) and Littelfuse (LFUS), and to distributors Arrow Electronics (ARW) and Avnet (AVT).
09/13/19
STFL
09/13/19
UPGRADE
Target $26
STFL
Buy
Kemet upgraded to Buy from Hold at Stifel
Stifel analyst Matthew Sheerin upgraded Kemet to Buy from Hold with an unchanged price target of $26. While the company is facing headwinds similar to competitors amid weakening demand and an inventory correction, its fundamentals have held up significantly better than comps due primarily to its product portfolio, Sheerin tells investors in a research note. The analyst says Kemet's top competitors are de-emphasizing multi-layer ceramic capacitors. As such, growth in the unit should offset weakness in other of Kemet's product segments, contends Sheerin. He expects the company's fundamentals to hold up better than peers given its "niche" position in multi-layer ceramic capacitors.
05/16/19
RILY
05/16/19
NO CHANGE
Target $26
RILY
Buy
Kemet price target raised to $26 from $24 at B. Riley FBR
B. Riley FBR analyst Craig Ellis raised his price target for Kemet to $26 from $24 saying the company's "strong" execution in Q4 and new five-year sales outlook should ease investor concerns. The analyst reiterates a Buy rating on the shares.
ICUI ICU Medical
$168.41

1.43 (0.86%)

08/08/19
RAJA
08/08/19
DOWNGRADE
Target $205
RAJA
Outperform
ICU Medical downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst Jayson Bedford downgraded ICU Medical to Outperform from Strong Buy and lowered his price target to $205 from $295. In a research note to investors, Bedford says that the company's earnings revision, while amplified by transient costs, is too big to ignore and the profitability of the business has been impaired, which impacts the ultimate value of the company. The analyst adds that he still believes ICU has a rightful place in the infusion therapy market and feels that, at some point, its share should improve, and while acknowledging that this setback is a hit to credibility, he still believes this management team can create value
08/08/19
RAJA
08/08/19
DOWNGRADE
RAJA
Outperform
ICU Medical downgraded to Outperform from Strong Buy at Raymond James
LONE Lonestar Resources
$2.88

0.08 (2.86%)

02/04/19
COWN
02/04/19
INITIATION
Target $8
COWN
Outperform
Lonestar Resources initiated with an Outperform at Cowen
Cowen analyst Gabe Daoud initiated Lonestar Resources with an Outperform rating, stating that the company has a proven track record of accretive Eagle Ford acquisitions at dollar-per-acre prices notably below the market average. He views their acquisition strategy favorably and sees the company continuing to boost net asset value and inventory at attractive valuations going forward. He also believes the company is positioning itself for an eventual takeout as larger peers become inventory starved in the Eagle Ford over the next few years. Daoud has a $7.50 price target on Lonestar Resources shares.
10/10/19
GHSC
10/10/19
DOWNGRADE
GHSC
Neutral
Lonestar Resources downgraded to Neutral from Buy at Seaport Global
10/10/19
GHSC
10/10/19
DOWNGRADE
GHSC
Neutral
Seaport Global downgrades Lonestar Resources to Neutral among 13 E&P downgrades
As previously reported, Seaport Global analyst Mike Kelly downgraded Lonestar Resources to Neutral from Buy. The rating change was among 13 downgrades made in the E&P sector by Kelly, who contends that "the 2020 oil macro set up is a mess." On Lonestar specifically, he is concerned about high debt levels and a lack of meaningful free cash flow if oil trades at $50 per barrel, stating that its "model is stretched" if more conservative commodity prices are assumed.
02/04/19
02/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Yelp (YELP) initiated with a Buy at Goldman Sachs while Groupon (GRPN) was initiated with a Neutral, and Match Group (MTCH) and Shutterfly (SFLY) were initiated with a Sell. 2. eHealth (EHTH) initiated with an Outperform at Evercore ISI. 3. Okta (OKTA) initiated with an Equal Weight at Morgan Stanley. 4. Lonestar Resources (LONE) initiated with an Outperform at Cowen. 5. Kopin (KOPN) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GO Grocery Outlet
$31.09

-0.06 (-0.19%)

08/14/19
JEFF
08/14/19
NO CHANGE
Target $50
JEFF
Buy
Grocery Outlet price target raised to $50 from $41 at Jefferies
Jefferies analyst Randal Konik raised his price target for Grocery Outlet to $50 from $41 saying the company's Q2 results illustrated its "unique" qualities. Grocery Outlet offers "predictable and stable" fundamentals, a "topnotch" leadership team, and scalable model, Konik tells investors in a post-earnings research note titled "WOW! 2Q Shows This Unicorn's Growth & Predictable Fundies: Reit. Buy, PT to $50." He believes Grocery Outlet has created a "defendable moat."
08/14/19
COWN
08/14/19
NO CHANGE
Target $48
COWN
Outperform
Grocery Outlet price target raised to $48 from $42 at Cowen
Cowen analyst Oliver Chen raised his price target on Grocery Outlet to $48 from $42 following Q2 results. The analyst said Grocery Outlet's off-price grocery model represents a compelling combination of high quality, national branded products at deep discounts. He is excited by its marketing and shopper engagement strategies as well as operational initiatives. Chen reiterated his Outperform rating on Grocery Outlet shares.
07/15/19
07/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Slack Technologies (WORK) initiated with an Outperform at William Blair, an Overweight at Barclays, and a Buy at Canaccord. 2. Grocery Outlet (GO) initiated with an Outperform at Telsey Advisory and Cowen, a Buy at Jefferies, an Equal Weight at Morgan Stanley, as well as a Neutral at Goldman Sachs, BofA/Merrill, and Guggenheim. 3. Atreca (BCEL) initiated with an Outperform at Evercore ISI and Cowen, as well as a Buy at Stifel. 4. Aqua America (WTR) initiated with a Buy at BofA/Merrill. 5. Anaplan (PLAN) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/15/19
GUGG
07/15/19
INITIATION
GUGG
Neutral
Grocery Outlet initiated with a Neutral at Guggenheim
Prior to the open, Guggenheim analyst John Heinbockel initiated Grocery Outlet with a Neutral rating, stating that he believes the company is well positioned for 5-10 years of sales growth greater than 10% and deserves a premium valuation. However, with the shares up 55% since the IPO, he thinks the growth potential is reflected in the current valuation.
CMLS Cumulus Media
$13.59

0.07 (0.52%)

12/07/18
WOLF
12/07/18
INITIATION
Target $14
WOLF
Peer Perform
Cumulus Media initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated Cumulus Media with a Peer Perform and $14 price target.
05/07/19
RILY
05/07/19
INITIATION
Target $20
RILY
Neutral
Cumulus Media initiated with a Neutral at B. Riley FBR
B. Riley FBR started Cumulus Media with a Neutral rating and $20 price target. The firm says post-bankruptcy "clouds linger" despite the attractive valuation at current share levels.
12/17/18
NBLE
12/17/18
UPGRADE
NBLE
Outperform
Cumulus Media upgraded to Outperform from Market Perform at Noble Financial
FGEN FibroGen
$35.37

-6.24 (-15.00%)

11/10/19
PIPR
11/10/19
NO CHANGE
PIPR
Piper Jaffray sees approval for FibroGen's roxadustat, but still has concerns
Piper Jaffray analyst Danielle Brill maintained a Neutral rating and $42 price target on FibroGen (FGEN). After getting more color on the MACE data from a meeting with management, speaking to a lead investigator, and listening to AstraZeneca's (AZN) call, Brill continues to expect approval of the drug, but also sees aspects that will drive debate, and a lack of clarity until FDA briefing documents for an Ad Com panel are released next year, which could be 6-10 months from now depending on priority. The analyst also still questions whether the labeling for the drug, if it is approved, will include a black box safety warning.
11/11/19
MZHO
11/11/19
NO CHANGE
Target $72
MZHO
Buy
FibroGen price target raised to $72 from $65 at Mizuho
Mizuho analyst Difei Yang raised her price target for FibroGen to $72 from $65 after the company reported MACE data from the global Phase 3 clinical trials of roxadustat. The data were positive with non-inferiority to placebo in the non dialysis-dependent setting and non-inferiority versus standard of care erythropoiesis stimulating agents in the dialysis-dependent setting, Yang tells investors in a research note. She believes the "path to approval is clear" and reiterates a Buy rating on FibroGen.
11/05/19
JEFF
11/05/19
NO CHANGE
Target $75
JEFF
Buy
Jefferies sees nothing new in FibroGen short report
Jefferies analyst Michael Yee does not see "anything really new" in yesterday's short report on FibroGen. The report is all based on earlier small Phase II/III studies that are already known, as well as on studies in China/Japan, where the drug has recently been approved, Yee tells investors in a research note. Moreover, FibroGen partner AstraZeneca (AZN) has publicly stated it is comfortable with the data, adds Yee. He keeps a Buy rating on FibroGen shares with a $75 price target
11/05/19
SBSH
11/05/19
NO CHANGE
Target $65
SBSH
Buy
FibroGen short report brings buying opportunity, says Citi
Citi analyst Joel Beatty believes yesterday's 8% stock price decline caused by a short report provides a good buying opportunity for FibroGen ahead of the Phase 3 Roxadustat results to be presented this Friday. The analyst continues to believe the FDA would be willing to approve Roxadustat based on the totality of the MACE data despite the lack of proven MACE non-inferiority. He keeps a Buy rating on FibroGen with a $65 price target.
DXC DXC Technology
$29.39

-0.69 (-2.29%)

09/26/19
WELS
09/26/19
NO CHANGE
Target $32
WELS
Market Perform
DXC Technology price target lowered to $32 from $46 at Wells Fargo
Wells Fargo analyst Ed Caso raised his price target for DXC Technology to $32 from $46 given the recent unexpected and abrupt resignation of CEO Mike Lawrie and the immediate shift to new CEO Mike Salvino. The analyst notes that investors are increasingly concerned whether DXC can actually revive organic growth without meaningfully reducing the EBITDA margin outlook, while Caso remains concerned about further reductions in the financial outlook. He expects the shares to remain volatile around current levels, and reiterates a Market Perform rating on the stock.
09/12/19
09/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Square (SQ) assumed with a Hold from Buy at Canaccord with analyst Joseph Vafi saying the stock will continue to react to changes in payment volume growth, which has been showing steady deceleration. 2. Deere (DE) and Caterpillar (CAT) were downgraded to Market Perform from Outperform at Wells Fargo. 3. Prudential (PRU) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Alex Scott saying Voya Financial (VOYA) has a better ability to beat earnings estimates in the near term as well as in 2020 and 2021 relative to Prudential. 4. Invesco (IVZ) downgraded to Neutral from Overweight at JPMorgan with analyst Kenneth Worthington saying continued Oppenheimer outflows "show few signs of slowing," making it unlikely for the stock to outperform despite a cheap valuation. 5. DXC Technology (DXC) was downgraded to In Line from Outperform at Evercore ISI and to Neutral from Positive at Susquehanna. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/08/19
MOFT
10/08/19
NO CHANGE
Target $36
MOFT
Neutral
DXC Technology price target lowered to $36 from $43 at MoffettNathanson
MoffettNathanson analyst Lisa Ellis noted that DXC Technology shares are down 70% over the past twelve months and the company now has a new CEO, making it a good time in her opinion to "hit the 'reset' button" and focus on what is next to come for the company rather than what has already happened. Given her view of the company's revenue, margin and free cash flow outlook Ellis maintains a Neutral rating on the stock and lowered her price target on DXC shares to $36 from $43.
09/12/19
EVER
09/12/19
DOWNGRADE
Target $34
EVER
In Line
Evercore ISI downgrades DXC Technology to In Line following CEO exit
As previously reported, Evercore ISI analyst Rayna Kumar downgraded DXC Technology to In Line from Outperform following the announcement of Mike Lawrie's retirement as President and CEO. Lawrie's track record of strong operational execution had been a key reason for recommending DXC stock and while Kumar likes successor Mike Salvino, the analyst believes the timing of the announcement may suggest that things could get worse before getting better. Kumar reduced the price target on DXC shares to $34 from $63.
BREW Craft Brew
$7.33

0.06 (0.83%)

09/06/19
MAXM
09/06/19
NO CHANGE
Target $16
MAXM
Buy
Craft Brew price target lowered to $16 from $21 at Maxim
Maxim analyst Stephen Anderson lowered his price target on Craft Brew to $16 after the company lowered its FY19 shipment guidance on its earnings call yesterday. The analyst still keeps his Buy rating on the shares, anticipating 2020 improvement as Craft Brew works through its inventory issues and "rationalizes its SG&A structure."
09/19/19
MKMP
09/19/19
INITIATION
Target $16
MKMP
Neutral
Craft Brew initiated with a Neutral at MKM Partners
MKM Partners analyst Bill Kirk initiated Craft Brew with a Neutral and $16 price target.
09/06/19
BMOC
09/06/19
NO CHANGE
Target $10
BMOC
Market Perform
Craft Brew price target lowered to $10 from $12 at BMO Capital
BMO Capital analyst Amit Sharma lowered his price target on Craft Brew (BREW) to $10 and kept his Market Perform rating, saying he sees "little likelihood" of a material stock price recovery after AB InBev (BUD) passed on fully acquiring the company. The analyst notes that while its management indicated that all strategic options are still on the table, he sees the potential for shareholder-friendly outcome as "unlikely".
09/05/19
COWN
09/05/19
NO CHANGE
Target $14
COWN
Outperform
Craft Brew price target lowered to $14 from $23 at Cowen
Cowen analyst Vivien Azer lowered her price target on shares of Craft Brew Alliance (BREW) to $14 from $23 after the company updated its FY19 guidance and following the recent news that Anheuser-Busch (BUD) declined its opportunity to make an offer to acquire the rest of the company's shares.
LYV Live Nation
$64.47

1.31 (2.07%)

10/08/19
MSCO
10/08/19
INITIATION
Target $75
MSCO
Equal Weight
Live Nation initiated with an Equal Weight rating at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne initiated coverage of Live Nation with an Equal Weight rating and $75 price target. While the company benefits from a leading position in the growing live events industry, consensus estimates call for double-digit adjusted operating income growth over the next four years and the stock's multiple has expanded by 40% in the last three years, leaving the stock as "a fairly consensus long priced for perfection," Swinburne tells investors.
11/11/19
EVER
11/11/19
UPGRADE
Target $73
EVER
Outperform
Live Nation upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst David Joyce upgraded Live Nation Entertainment to Outperform from In Line with a $73 price target.
11/11/19
11/11/19
UPGRADE
Target $73

Outperform
Live Nation upgraded to Outperform from In Line at Evercore ISI
As previously reported, Evercore ISI analyst David Joyce upgraded Live Nation to Outperform from In Line with a $73 price target. The analyst believes Live Nation shares have "pulled back needlessly" following its Q3 earnings results, and recommended taking advantage of the pullback. Joyce sees 2020 as another year of "strong, double-digit" growth in adjusted operating income, or AOI, seeing 2020 AOI of $1.1B. He added that "concert-going is a recession-resilient business model" and as such, he doesn't see any potential recession impact.
10/25/19
JEFF
10/25/19
NO CHANGE
Target $84
JEFF
Buy
Basement East booking positive for Live Nation shares, says Jefferies
Jefferies analyst Khoa Ngo says data work suggests Live Nation Entertainment serving as the exclusive booking agent of The Basement East venue should be additive over the long-term and positive for shares. While financial details were not disclosed, it is important to quantify the venue's popularity to assess the value capture opportunities, which "should be plenty," Ngo tells investors in a research note titled "Honky Tonk Value Capture." The analyst reiterates a Buy rating on Live Nation shares with an $84 price target.
FLNT Fluent
$2.54

0.11 (4.53%)

03/14/19
BRRR
03/14/19
NO CHANGE
Target $8
BRRR
Outperform
Fluent price target raised to $8 from $6 at Barrington
Barrington analyst James Goss raised his price target for Fluent to $8 from $6 after the company's Q4 results topped expectations. The analyst sees "continued momentum" for Fluent's "growing business" and keeps an Outperform rating on the shares.
05/09/19
05/09/19
UPGRADE
Target $8.5

Buy
Fluent upgraded to Buy at Roth Capital
As previously reported, Roth Capital analyst William Gibson upgraded Fluent to Buy from Neutral as cash generation continues and based on a more select group of comparable companies. The analyst also raised his price target on the shares to $8.50 from $5.50.
03/14/19
ROTH
03/14/19
DOWNGRADE
Target $5.5
ROTH
Neutral
Fluent downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst William Gibson downgraded Fluent to Neutral from Buy, while raising his price target on the shares to $5.50 from $4.50. The analyst notes that Fluent earned over $1.6M or 2c per share on 25% year over year growth in revenue to $70.8M, with his estimate at nearly $5.4M profit or 7c per share on revenue of $67M, while the adjusted EBITDA of $11.1M was also below his $13.9M estimate. The profit difference versus his estimate was caused by a margin squeeze as the company spent heavily to drive consumers to its web sites and venues for additional growth to meet customer demand, he contends.
05/09/19
ROTH
05/09/19
UPGRADE
ROTH
Buy
Fluent upgraded to Buy from Neutral at Roth Capital
ASUR Asure Software
$9.20

0.01 (0.11%)

08/12/19
ADAM
08/12/19
NO CHANGE
Target $12
ADAM
Buy
Asure Software recent selloff seems extreme, says Canaccord
Canaccord analyst David Hynes said Asure Software posted solid Q2 results as revenue and EBITDA beat expectations. The analyst said guidance was disappointing and represented another financial blip when trying to restore investor confidence on its stability of forward projections. He believes the company is taking logical steps to a foundation for more consistent execution and as such suspects the selloff is a bit extreme. Hynes reiterated his Buy rating and lowered his price target to $12 from $13 on Asure Software shares.
03/05/19
GSCO
03/05/19
DOWNGRADE
GSCO
Sell
Goldman Sachs cuts GAP Airports, Asur to Sell on lower growth forecast
Goldman Sachs analyst Bruno Amorim downgraded airports Asur (ASUR) and GAP (PCA) to Sell from Neutral and Buy respectively as part of his broader research note on the Mexico Transportation sector. The analyst says the Q4 results in the industry suggests that capacity constraints from airlines, "driven by market leader Aeromexico's decision to potentially shrink domestic capacity", could curb airport growth. The analyst also issues a double-notch upgrade of Volaris (VLRS) to Buy from Sell as part of his research note, forecasting the airline to enter a margin expansion phase after a "sharp correction" in its EBIT and amid "concrete signs" that its unit revenues RASM metric has bottomed.
04/10/19
BRRR
04/10/19
NO CHANGE
Target $15
BRRR
Outperform
Asure Software valuation provides attractive entry point, says Barrington
Barrington analyst Vincent Colicchio believes the current valuation provides an attractive entry point into Asure Software. Trading at a large discount to the peer group average, Asure shares are undervalued, Colicchio tells investors in a research note. He believes the large size of the company's target markets and the economic benefits associated with its acquisition strategy "justify a significantly higher multiple." The analyst keeps an Outperform rating on Asure Software with a $15 12-month price target.
10/10/19
BBVA
10/10/19
DOWNGRADE
Target $175
BBVA
Market Perform
Asure Software downgraded to Market Perform from Outperform at BBVA
BBVA analyst Mauricio Hernandez Prida downgraded Asure Software to Market Perform from Outperform with a $175 price target.
UGI UGI Corporation
$46.21

-0.35 (-0.75%)

04/03/19
BOFA
04/03/19
UPGRADE
BOFA
Buy
UGI Corporation upgraded to Buy from Neutral at BofA/Merrill
04/05/19
JEFF
04/05/19
UPGRADE
JEFF
Buy
UGI Corporation upgraded to Buy from Hold at Jefferies
Jefferies analyst Christopher Sighinolfi upgraded UGI Corporation to Buy from Hold.
04/05/19
JEFF
04/05/19
NO CHANGE
JEFF
Buy
Jefferies upgrades UGI, downgrades AmeriGas after deal announcement
As previously reported, Jefferies analyst Christopher Sighinolfi upgraded UGI Corporation (UGI) to Buy from Hold and downgraded AmeriGas Partners (APU) to Hold from Buy after the company's recent announcement that UGI will acquire AmeriGas's publicly-held LP units for cash and stock. He views the deal as a "logical solution" with benefits for both and thinks the merger frees up more than $200M per year in cash for UGI while also resulting in EPS accretion and enhanced optionality without any step-out in risk. Since the merger terms implies a $37.50/unit valuation for AmeriGas, the total return potential falls short of the firm's Buy threshold, Sighinolfi said.
04/03/19
04/03/19
UPGRADE
Target $58

Buy
UGI Corporation upgraded to Buy on valuation at BofA/Merrill
As previously reported, BofA/Merrill upgraded UGI Corporation to Buy from Neutral with a $58 price target. Analyst Dennis Coleman views the sell-off in shares following the acquisition of AmeriGas (APU) as overdone and would be a buyer of shares.
HBM Hudbay Minerals
$3.66

-0.09 (-2.40%)

10/14/19
FBCO
10/14/19
INITIATION
FBCO
Outperform
Hudbay Minerals assumed with an Outperform at Credit Suisse
Credit Suisse analyst Fahad Tariq assumed coverage of Hudbay Minerals with an Outperform rating and C$8.75 price target. The analyst made no changes to the firm's estimates, rating or target price in conjunction with the assumption of primary coverage.
05/07/19
ADAM
05/07/19
UPGRADE
ADAM
Buy
Hudbay Minerals upgraded to Buy from Hold at Canaccord
05/10/19
05/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Hudbay Minerals (HBM) downgraded to Market Perform from Outperform at BMO Capital wwith analyst Jackie Przybylowski saying the company is entering a "naturally relatively slow period" in its news flow. 2. Nevro (NVRO) downgraded to Hold from Buy at Canaccord with analyst Jason Mills stating that while he expected Q1 would be "ugly," results were "a little worse" than he expected. 3. Interxion (INXN) downgraded to Perform from Outperform at Oppenheimer with analyst Tim Horan citing valuation. 4. Entegris (ENTG) downgraded to Neutral from Buy at Citi with analyst Atif Malik saying he expects consumable stocks tied to overall wafer or display starts to "slow down" in the second half of 2019. 5. SharpSpring (SHSP) downgraded to Hold from Buy at Craig-Hallum with analyst Mike Malouf stating the company is effectively competing against market leaders and gaining share, but that its increasing marketing and R&D spending will push out profitability. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/10/19
BMOC
05/10/19
DOWNGRADE
BMOC
Market Perform
Hudbay Minerals downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Jackie Przybylowski downgraded Hudbay Minerals to Market Perform from Outperform saying the company is entering a "naturally relatively slow period" in its news flow. Hudbay is entering a higher period of capital spending with the permitting and expected sanction of Rosemont for construction in 2020, Przybylowski tells investors in a research note. As such, she sees fewer near-term catalysts for the shares. The analyst has a C$10.75 price target for the stock.
FPI Farmland Partners
$6.66

-0.125 (-1.84%)

11/13/18
RILY
11/13/18
DOWNGRADE
Target $7.5
RILY
Neutral
Farmland Partners downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Craig Kucera downgraded Farmland Partners to Neutral with an unchanged price target of $7.50. The analyst cites valuation and a lack of visibility into 2019 for the downgrade.
RETA Reata Pharmaceuticals
$213.52

1.48 (0.70%)

10/15/19
JEFF
10/15/19
NO CHANGE
Target $254
JEFF
Buy
Reata Pharmaceuticals price target raised to $254 from $128 at Jefferies
Jefferies analyst Maury Raycroft raised his price target for Reata Pharmaceuticals to $254 from $128 and and maintained a Buy rating, telling investors in a research note that the company's to-line data from the registrational Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich's ataxia seem "impressive" on the primary endpoint, and believes the unmet need and totality of data will be enough to get the drug approved. Raycroft says the positive FA results were "unexpected."
10/16/19
STFL
10/16/19
NO CHANGE
Target $210
STFL
Buy
Reata Pharmaceuticals price target raised to $210 from $135 at Stifel
Stifel analyst Adam Walsh increased his price target on Reata Pharmaceuticals to $210 from $135 after omaveloxolone in patients with Friedreich's ataxia hit the "FDA-blessed" primary endpoint of placebo-corrected mFARS in the MOXIe trial. He, and his key-opinion leader consultant, think omaveloxolone first-pass approval is likely based on the trial results reported, especially given the "benign" safety and tolerability, Walsh tells investors. Beyond omaveloxolone, he remains bullish ahead of Alport data due out this quarter, Walsh added.
11/04/19
CANT
11/04/19
NO CHANGE
Target $250
CANT
Overweight
Reata Pharmaceuticals price target raised to $250 from $180 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Reata Pharmaceuticals to $250 from $180 and keeps an Overweight rating on the shares. The analyst says results from his recent key opinion leader due diligence enhances his conviction in the clinical value for bardoxolone's Phase 3 Cardinal study in Alport syndrome.
10/16/19
LTCO
10/16/19
NO CHANGE
Target $239
LTCO
Buy
Reata Pharmaceuticals price target raised to $239 from $133 at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan raised his price target for Reata Pharmaceuticals to $239 from $133 after the company announced positive topline data from Part 2 of the MOXIe registrational trial of omaveloxolone in patients with Friedreich's ataxia. Importantly, omaveloxolone treatment not only halted the progression of the disease but actually showed improvement in the largest Friedreich's trial to date, Kaplan tells investors in a research note. He believes the data are sufficient as a registrational study for approval of omaveloxolone in Friedreich's Ataxia. The analyst reiterates a Buy rating on Reata Pharmaceuticals and says his new price target reflects to the increased probability of approval of omaveloxolone in Friedreich's ataxia.
JCOM j2 Global
$100.62

0.23 (0.23%)

07/10/19
JMPS
07/10/19
NO CHANGE
Target $100
JMPS
Outperform
JMP Securities positive on j2 Global given profitability, compelling valuation
JMP Securities analyst Patrick Walravens kept his Outperform rating and $100 price target on j2 Global ahead of his meeting with its CFO Scott Turicchi tomorrow. The analyst says he remains positive on the company given its "effective" M&A strategy, "compelling" valuation, and high level of profitability with a 35% free cash flow yield reported in Q1.
04/22/19
DADA
04/22/19
NO CHANGE
Target $110
DADA
Buy
j2 Global price target raised to $110 from $100 at DA Davidson
DA Davidson analyst Rishi Jaluria raised his price target on j2 Global to $110 and kept his Buy rating after meeting with its CFO . Following the discussions, the analyst expects growth in the company's digital media business to come from "performance marketing and subscription", which will drive the management's M&A strategy to opportunities with "performance / subscription revenue stream". Jaluria adds that execution at Everyday Health, which J2 Global acquired last year, has "improved meaningfully, driven by new leadership and a change in philosophy around relationships with pharmaceutical companies."
04/03/19
SBSH
04/03/19
NO CHANGE
Target $95
SBSH
Buy
j2 Global price target raised to $95 from $86 at Citi
Citi analyst Nicholas Jones raised his price target for j2 Global to $95 from $86 after taking over coverage of the name from Walter Pritchard. He keeps a Neutral rating on j2. The company's growth prospects from cloud services will be "slow at best," balanced by moderate growth in digital media, Jones tells investors in a research note. However, j2's acquisition strategy "creates a floor" to the share price since the company has a track record of completing accretive deals, says the analyst. Nonetheless, the current economic climate of high valuations and a looming recession create "significant execution risk" in j2 Global's ability to find accretive opportunities, he adds.
05/09/19
WEDB
05/09/19
NO CHANGE
Target $105
WEDB
Outperform
j2 Global price target raised to $105 from $95 at Wedbush
Wedbush analyst Daniel Ives raised his price target for j2 Global to $105 from $95 to reflect his increasing estimates and growing confidence in the story over the coming year. The analyst notes that j2 Global delivered Q1 results that "handily beat" the Street across the board and in an "unprecedented move" for the company raised its 2019 guidance in a "clear position of strength and confidence" into the rest of the year on the heels of healthy business momentum and a strong M&A pipeline. Ives reiterates an Outperform rating on the shares.
PCG PG&E
$6.24

-0.23 (-3.55%)

10/28/19
WOLF
10/28/19
DOWNGRADE
Target $19
WOLF
Peer Perform
Clearway Energy downgraded to Peer Perform on PG&E risk at Wolfe Research
Wolfe Research analyst Steve Fleishman downgraded Clearway Energy (CWEN) to Peer Perform from Outperform with a price target of $19, down from $21. The analyst notes Clearway has the most exposure to PG&E (PCG) with 30% of consolidated CAFD derived from the company.
10/25/19
SBSH
10/25/19
NO CHANGE
Target $5
SBSH
Sell
Kincade fire increases probability of PG&E shares going to zero, says Citi
As of this morning, the Kincade fire covered ten thousand acres, was not contained and caused damage to two structures, Citi analyst Praful Mehta tells investors in a research note. It is not clear if PG&E equipment was involved, says Mehta, who believes shareholders are worried "and should be." It is important to note that any damages from a 2019 fire may be treated as post-petition claims that could recover 100 cents on the dollar, Mehta points out. Per AB1054, the wildfire fund is only liable to pay 40% of the damages for a 2019 fire. Further, the analyst believes that if Kindcade causes significant damage, PG&E's claim estimation and financing plans are likely to get delayed. Given the already very tight schedule to hit the June 2020 timeline per AB1054, a significant fire puts a timely exit and AB1054 at risk, says Mehta. As a result, the analyst believes the Kincade fire increases the probability of a zero share price for PG&E. While the bondholder plan wipes out existing shareholders, a large 2019 wildfire liability will also result in a similar outcome "purely from the liabilities and the associated need for additional financing," Mehta argues. He keeps a Sell rating on PG&E shares with a $5 price target. The probability of a zero equity value continues to increase, he says.The stock in premarket trading is down 28%, or $2.04, to $5.16.
10/11/19
10/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Crowdstrike (CRWD) downgraded to Sell from Neutral at Goldman Sachs with analyst Heather Bellini stating while CrowdStrike is very well positioned in the market for endpoint security, a "blue sky analysis" suggests this is likely priced in at current share levels. 2. Terex (TEX) downgraded to Underweight from Equal Weight at Barclays with analyst Adam Seiden expecting the rental equipment market to move from equilibrium to oversupplied by 2020. 3. Delta Air Lines (DAL) downgraded to Hold from Buy at Argus with analyst John Staszark saying that while Delta is among the best managed airlines, he thinks better returns are available elsewhere, as Delta is facing prospects for rising costs and slowing revenue growth. 4. PG&E (PCG) downgraded to Sell from Neutral at Citi with analyst Praful Mehta seeing a 75% chance of the stock going to zero after Judge Montali terminated PG&E's exclusive right to advance a plan of reorganization. 5. Canopy Growth (CGC) downgraded to Underperform from Hold at Jefferies with analyst Owen Bennett saying despite the recent selloff in shares, Canopy is the most expensive name across the cannabis space. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/19
MSCO
10/25/19
NO CHANGE
Target $16
MSCO
Equal Weight
Morgan Stanley says report raises risk that PG&E equipment involved in fire
Morgan Stanley analyst Stephen Byrd said PG&E filed an incident report on Thursday evening about the Kincade Fire which contained details that, while not necessarily indicating that the utility's equipment caused the fire, raise the risk that PG&E equipment could have been involved. He has an Equal Weight rating and $16 price target on PG&E shares, which are down about 20% to $5.72 at time of writing, off their worst levels from earlier in the pre-market session.

TODAY'S FREE FLY STORIES

11:09
12/12/19
12/12
11:09
12/12/19
11:09
General news
5-Yr TIPS Announcement CUSIP Number data reported »

5-Yr TIPS Announcement…

11:09
12/12/19
12/12
11:09
12/12/19
11:09
General news
5-Yr TIPS Announcement Offering Amount data reported »

5-Yr TIPS Announcement…

EH

Ehang

$0.00

(0.00%)

11:09
12/12/19
12/12
11:09
12/12/19
11:09
Syndicate
Breaking Syndicate news story on Ehang »

Ehang opens at $12.55,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SHAK

Shake Shack

$59.20

0.29 (0.49%)

11:05
12/12/19
12/12
11:05
12/12/19
11:05
Options
Shake Shack call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jan

MCK

McKesson

$144.02

0.62 (0.43%)

11:02
12/12/19
12/12
11:02
12/12/19
11:02
Hot Stocks
McKesson selected to continue as prime pharmaceutical supplier for VA »

McKesson Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$146.49

2.42 (1.68%)

10:58
12/12/19
12/12
10:58
12/12/19
10:58
Downgrade
Caterpillar rating change  »

Caterpillar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BILL

Bill.com

$0.00

(0.00%)

10:58
12/12/19
12/12
10:58
12/12/19
10:58
Syndicate
Breaking Syndicate news story on Bill.com »

Bill.com indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

EH

Ehang

$0.00

(0.00%)

10:58
12/12/19
12/12
10:58
12/12/19
10:58
Syndicate
Breaking Syndicate news story on Ehang »

Ehang indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BBU

Brookfield Business Partners

$40.99

(0.00%)

, GNW

Genworth

$4.60

0.135 (3.03%)

10:55
12/12/19
12/12
10:55
12/12/19
10:55
Hot Stocks
Genworth completes Genworth MI Canada stake sale to Brookfield Business Partners »

Genworth Financial (GNW)…

BBU

Brookfield Business Partners

$40.99

(0.00%)

GNW

Genworth

$4.60

0.135 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

10:55
12/12/19
12/12
10:55
12/12/19
10:55
General news
Treasury 30-year auction outlook: the $16 B reopening rounds out this week's auctions »

Treasury 30-year auction…

TSLA

Tesla

$359.21

6.81 (1.93%)

10:51
12/12/19
12/12
10:51
12/12/19
10:51
Periodicals
Tesla loses third general counsel this year, Bloomberg Law says »

Jonathan Chang, who was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

GE

General Electric

$11.42

0.44 (4.01%)

10:46
12/12/19
12/12
10:46
12/12/19
10:46
On The Fly
GE jumps as UBS predicts positive inflection point in 2020 »

Shares of General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

BILL

Bill.com

$0.00

(0.00%)

10:45
12/12/19
12/12
10:45
12/12/19
10:45
Syndicate
Breaking Syndicate news story on Bill.com »

Bill.com indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ABBV

AbbVie

$88.15

1.46 (1.68%)

10:45
12/12/19
12/12
10:45
12/12/19
10:45
Options
AbbVie call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
12/12/19
12/12
10:45
12/12/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
12/12/19
12/12
10:45
12/12/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

10:45
12/12/19
12/12
10:45
12/12/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
12/12/19
12/12
10:45
12/12/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

SBUX

Starbucks

$88.83

2.24 (2.59%)

, BHC

Bausch Health

$31.07

1.745 (5.95%)

10:44
12/12/19
12/12
10:44
12/12/19
10:44
On The Fly
GE, Starbucks, Bausch upgrades among today's top analyst calls »

Check out today's top…

SBUX

Starbucks

$88.83

2.24 (2.59%)

BHC

Bausch Health

$31.07

1.745 (5.95%)

AAPL

Apple

$271.38

0.67 (0.25%)

HD

Home Depot

$213.65

1.69 (0.80%)

MMM

3M

$170.04

1.31 (0.78%)

GE

General Electric

$11.42

0.44 (4.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Dec

  • 29

    Jan

  • 29

    Jan

  • 25

    Feb

EH

Ehang

$0.00

(0.00%)

10:39
12/12/19
12/12
10:39
12/12/19
10:39
Syndicate
Ehang indicated to open at $12.25, IPO priced at $12.50 »

Ehang (EH) 3.2M share IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

WDDMF

WeedMD

$0.00

(0.00%)

, ACB

Aurora Cannabis

$2.46

(0.00%)

10:37
12/12/19
12/12
10:37
12/12/19
10:37
On The Fly
Rising High: An exclusive talk with medical-grade cannabis producer WeedMD »

In this edition of…

WDDMF

WeedMD

$0.00

(0.00%)

ACB

Aurora Cannabis

$2.46

(0.00%)

TLRY

Tilray

$18.68

0.49 (2.69%)

ZYNE

Zynerba

$5.68

0.06 (1.07%)

CGC

Canopy Growth

$20.35

0.05 (0.25%)

CTST

CannTrust

$0.81

-0.0102 (-1.24%)

CRON

Cronos Group

$6.89

0.07 (1.03%)

IGC

India Globalization Capital

$0.67

0.0047 (0.71%)

CVSI

CV Sciences

$0.00

(0.00%)

CANN

General Cannabis

$0.00

(0.00%)

TCNNF

Trulieve Cannabis

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 17

    Dec

PTVCA

Protective Insurance

$15.36

(0.00%)

10:36
12/12/19
12/12
10:36
12/12/19
10:36
Hot Stocks
Breaking Hot Stocks news story on Protective Insurance »

Protective Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$178.55

-1.315 (-0.73%)

10:35
12/12/19
12/12
10:35
12/12/19
10:35
Options
Autodesk put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILL

Bill.com

$0.00

(0.00%)

10:35
12/12/19
12/12
10:35
12/12/19
10:35
Syndicate
Breaking Syndicate news story on Bill.com »

Bill.com indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

USO

United States Oil Fund

$12.45

0.16 (1.30%)

10:34
12/12/19
12/12
10:34
12/12/19
10:34
General news
EIA natural gas storage change for week ending December 6 »

Gas inventories 73 Bcf…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.